TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06660992: Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-cystic Fibrosis Bronchiectasis

Sponsor: Haisco Pharmaceutical Group Co., Ltd. · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 669 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$23,401,600

Rescue Site Savings

+$15,430,430

Unlock Full NCT06660992 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06660992 Rescue Dossier →